Table II.

Neuroanatomy data of psoriatic lesional and non-lesional skin in PSORITUS

Factor	Baseline		Week 16	Week 32
	LS (n = 47)	NL (n = 47)	LS (n = 47)	SEC LS (n = 29)	Placebo LS (n = 18)
IENFD rel. to NL	–2.52 [–0.90]	–	0.23 [–1.02]	0.32 [–1.88]	–0.61 [–0.52]
IENFL, µm	34.7 [28.1;44.6]	23.0 [18.7;28.2]	26.8 [20.9;36.4]	23.9* [21.5;32.2]	29.6* [25.5;33.5]
Epidermal height, µm	163.7 [126.9;203.0]	50.9 [43.6;60.5]	55.0 [47.8;67.9]	57.2 [48.9;76.3]	60.1 [49.4;110.75]
IENFL rel. to epidermal height	0.24 [0.17;0.30]	0.48 [0.32;0.61]	0.48 [0.39;0.60]	0.42 [0.31;0.50]	0.44 [0.28;0.61]

Median [interquartile range] of neuroanatomical data at baseline and after week 16 and 32, respectively. No significant differences at the endpoint (week 32) except for IENFL (p = 0.044). Statistics: independent samples: Mann–Whitney U test, significance at week 32 marked in bold; *p < 0.05.

IENFD: intraepidermal nerve fibre density; IENFL: intraepidermal nerve fibre length; LS: lesional; NL: non-lesional; n.s.: not significant; rel.: relative; SEC: secukinumab.